These data suggest that a graded dose of FBXO32 and FOXO1 may be beneficial when PB cells carrying FBXO32 and FOXO1 summon into the brain in response to Alzheimer’s disease (AD) perturbation (docking station PB cells). This evidence concerns the gene FOXO1 and early-onset autosomal dominant Alzheimer disease.